Amundi Buys 12,899 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Amundi increased its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 193.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 19,583 shares of the company’s stock after purchasing an additional 12,899 shares during the period. Amundi’s holdings in Amphastar Pharmaceuticals were worth $717,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of AMPH. Smartleaf Asset Management LLC increased its position in Amphastar Pharmaceuticals by 222.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 715 shares of the company’s stock worth $26,000 after purchasing an additional 493 shares during the last quarter. Parkside Financial Bank & Trust increased its position in Amphastar Pharmaceuticals by 806.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 979 shares of the company’s stock worth $36,000 after purchasing an additional 871 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. increased its position in Amphastar Pharmaceuticals by 53.4% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 1,144 shares of the company’s stock worth $56,000 after purchasing an additional 398 shares during the last quarter. KBC Group NV increased its position in Amphastar Pharmaceuticals by 43.1% in the fourth quarter. KBC Group NV now owns 2,159 shares of the company’s stock worth $80,000 after purchasing an additional 650 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in Amphastar Pharmaceuticals by 90.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 4,203 shares of the company’s stock worth $156,000 after purchasing an additional 1,992 shares during the last quarter. Institutional investors own 65.09% of the company’s stock.

Insiders Place Their Bets

In other news, CFO William J. Peters sold 4,231 shares of Amphastar Pharmaceuticals stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now directly owns 97,363 shares in the company, valued at approximately $2,681,377.02. This trade represents a 4.16 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 27.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on AMPH shares. Piper Sandler cut shares of Amphastar Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $66.00 to $36.00 in a research report on Tuesday, February 4th. Wells Fargo & Company assumed coverage on Amphastar Pharmaceuticals in a research report on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 price target for the company.

Amphastar Pharmaceuticals Stock Up 1.8 %

Shares of AMPH opened at $27.86 on Thursday. The company has a market cap of $1.33 billion, a PE ratio of 9.29, a P/E/G ratio of 2.19 and a beta of 0.77. The business has a fifty day moving average of $32.25 and a 200 day moving average of $40.80. Amphastar Pharmaceuticals, Inc. has a 52-week low of $25.89 and a 52-week high of $53.96. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.